EB 病毒相关的细胞免疫治疗。

Epstein‒Barr virus-associated cellular immunotherapy.

机构信息

First Center Clinic College of Tianjin Medical University, Tianjin, China.

Department of Hematology, Tianjin First Central Hospital, Tianjin, China.

出版信息

Cytotherapy. 2023 Sep;25(9):903-912. doi: 10.1016/j.jcyt.2023.04.003. Epub 2023 May 6.

DOI:10.1016/j.jcyt.2023.04.003

PMID:37149797

Abstract

Epstein‒Barr virus (EBV) is a human herpes virus that is saliva-transmissible and universally asymptomatic. It has been confirmed that more than 90% of the population is latently infected with EBV for life. EBV can cause a variety of related cancers, such as nasopharyngeal carcinoma, diffuse large B-cell lymphoma, and Burkitt lymphoma. Currently, many clinical studies have demonstrated that EBV-specific cytotoxic T lymphocytes and other cell therapies can be safely and effectively transfused to prevent and treat some diseases caused by EBV. This review will mainly focus on discussing EBV-specific cytotoxic T lymphocytes and will touch on therapeutic EBV vaccines and chimeric antigen receptor T-cell therapy briefly.

摘要

EB 病毒（EBV）是一种可通过唾液传播且普遍无症状的人类疱疹病毒。已经证实，超过 90%的人口终生潜伏感染 EBV。EBV 可导致多种相关癌症，如鼻咽癌、弥漫性大 B 细胞淋巴瘤和伯基特淋巴瘤。目前，许多临床研究表明，EBV 特异性细胞毒性 T 淋巴细胞和其他细胞疗法可以安全有效地输注，以预防和治疗一些由 EBV 引起的疾病。本综述将主要集中讨论 EBV 特异性细胞毒性 T 淋巴细胞，并简要提及治疗性 EBV 疫苗和嵌合抗原受体 T 细胞疗法。